Vertex Pharmaceuticals | VRTX - Interest Income


Vertex Pharmaceuticals reported $114.8M in Interest Income for its fiscal quarter ending in March of 2026.





Interest Income Change Date
AbbVie USD 59M 13M Dec/2025
Acadia Pharmaceuticals USD 8.33M 86K Dec/2025
Agios Pharmaceuticals USD 12.41M 959K Dec/2025
Alnylam Pharmaceuticals USD 26.63M 2.05M Dec/2025
Arrowhead Research USD 9.69M 637K Dec/2025
Biogen USD 37.9M 700K Mar/2026
BioMarin Pharmaceutical USD 22.56M 3.35M Mar/2026
Gilead Sciences USD 95M 7M Dec/2025
Incyte USD 33.69M 2.93M Mar/2026
Insmed USD 765K 55K Sep/2024
Ionis Pharmaceuticals USD -0.66 0.29 Dec/2024
J&J USD 2.14 237M Mar/2026
Merck USD 69M 27M Dec/2025
Moderna USD 70M 3M Dec/2025
Pfizer USD 115M 51M Mar/2026
Puma Biotechnology USD 0.41 0.5 Sep/2024
Regeneron Pharmaceuticals USD 193.3M 18.2M Dec/2025
Sanofi EUR 33M 81M Dec/2025
Sarepta Therapeutics USD 8.74M 359K Dec/2025
Ultragenyx Pharmaceutical USD 6.51M 649K Dec/2025
United Therapeutics USD 43.2M 3.2M Dec/2025
Vertex Pharmaceuticals USD 114.8M 7.1M Mar/2026